4.2 ASIA PACIFIC: RWE SOLUTIONS MARKET, BY END USER AND COUNTRY (2021) Business Solutions including all features. 13.1 DISCUSSION GUIDE Most pharmaceutical, biopharmaceutical, and medical device companies continue to invest heavily in the development of novel drugs and devices. 8.4 POST-MARKET SURVEILLANCE 6.5.2.2 Europe The summary data allow users to explore the trends in fuel economy, CO 2, and vehicle attributes for model years 1975-2022. 10.3.5 SPAIN Figures were rounded to provide a better understanding of the statistic. 10.3.1 GERMANY 8.2.2.1 High prevalence of CVD to drive growth It also determines the outcomes based on much larger data samples, reduces costs, and improves the efficiency of clinical trials. Real-world evidence (RWE) is clinical evidence gathered via real-world data (RWD) analysis on a medical product's use and potential benefits or risks. An assessment of the competitive landscape and market shares for major companies. Poor data quality costs the US economy up to $3.1 trillion yearly. Visual Data Discovery Market Size: Overview, Share, Trends with Current Market Scenario, 2027 Published: Feb. 23, 2023 at 1:20 a.m. A series of well-publicized recalls, and regulatory settlements have left policymakers and consumers questioning the safety of medical products and their trust in manufacturers. What are the major revenue pockets in the real world evidence solutions market currently? 12.1.1 IQVIA HOLDINGS INC. RWE helps and provides a means for demonstrating value, ranging from confirming randomized trial benefits in real-world populations to a fuller characterization of resource impacts. The data for GDP at purchasing power parity has also been rebased using the new International Comparison Program price surveys and extrapolated to 2007. 7.3.2 INTEGRATED DATA SETS 5.2.1.4 Increased R&D spending for the development of new pharmaceutical products and medical devices 10.3.3.1 High number of oncology clinical trials in France to drive market growth FIGURE 43 REAL WORLD EVIDENCE SOLUTIONS MARKET RANKING, BY KEY PLAYER, 2021 6.4.4 THREAT OF SUBSTITUTES The global real world evidence solutions market in terms of revenue was estimated to be worth $1.5 billion in 2022 and is poised to reach $2.9 billion by 2027, growing at a CAGR of 15.2% from 2022 to 2027. To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, solution portfolios, and recent financials, To track and analyze competitive developments such as acquisitions, product launches, partnerships, and expansions in the real world evidence solutions market, Detailed analysis and profiling of additional market players (up to 5), Further breakdown of the RoAPAC market into Australia, South Korea, New Zealand, Hong Kong, Singapore, and other countries, Further breakdown of the RoE market into Switzerland, Russia, the Netherlands, Nordic countries, and other countries, Further breakdown of the Latin America market into Brazil, Mexico, and the Rest of Latin America, Get Data as per your Format and Definition, Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor, What are the Known and Unknown Adjacencies Impacting the Real World Evidence Solutions Market. 12.1.11 SAS INSTITUTE Thus, stakeholders are reluctant to utilise evidence lacking a standard data generation procedure. Methods: This review explores how hybrid study designs that include features of RCTs and studies with real-world . By clicking Accept all you agree that Yahoo and our partners will process your personal information, and use technologies such as cookies, to display personalised ads and content, for ad and content measurement, audience insights, and product development. With rising challenges, healthcare payers are increasingly focused on evidence of clinical value for making market access & reimbursement/coverage decisions. REDDING, Calif., March 10, 2022 /PRNewswire/ -- According to a new market research report titled "Real-World Evidence (RWE) Solutions Market by Component (Datasets [Clinical, Claims, Pharmacy, Integrated], Services), Application (Market Access, Oncology, Neurology, Post Market Surveillance), End User (Pharma Companies, Providers) - Global Forecast to 2028", published by Meticulous Research, the Real-World Evidence (RWE) solutions market is expected to grow at a CAGR of 11.8% from 2021 to 2028 to reach $4.4 billion by 2028. 7.3.1.4.1 Increasing need to access opinions on diseases and treatments across social media to drive growth $6.36 billion will be spent in the consumer segment. 6.2 REAL-WORLD DATA SOURCES FIGURE 2 PRIMARY SOURCES These companies are majorly focused on partnerships, collaborations, and agreements to accelerate the delivery of RWE datasets and consulting & analytics services and explore how real-world evidence can provide information for health technologies and improve clinical and cost-effectiveness. TABLE 46 RWE SOLUTIONS MARKET FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES, BY COUNTRY, 20202027 (USD MILLION) The following customization options are available for the report: Which are the different countries covered across the regions of the Global RWE Solutions Market? TABLE 95 FRANCE: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) You need a Statista Account for unlimited access. FIGURE 51 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2021) the market is growing at a steady rate and with the rising adoption of strategies by. TABLE 138 CHINA: RWE MARKET, BY APPLICATION, 20202027 (USD MILLION) June 7, 2021. 11.6.3 REGIONAL FOOTPRINT OF COMPANIES The top five markets in 2020 were: United States ($15.1 billion), China ($6.3 billion), Germany ($5.7 billion), Japan ($4.2 billion) and France ($2.7 billion). The increasing emphasis on clinical value evidence for choices to offer coverage and the rising cost of therapy is responsible for expanding the reimbursement/coverage and regulatory decision-making segment. FIGURE 9 DATA TRIANGULATION METHODOLOGY 4.4 REGIONAL MIX: REAL WORLD EVIDENCE SOLUTIONS MARKET (20222027) Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to details. Real world data (RWD) plays an increasingly important role in clinical research and health care decision making; the 2016 US 21st Century Cures Act places additional emphasis on the use of these types of data to support regulatory decision making. Hence, the rising emphasis on using comprehensive RWE data is propelling the markets growth.Market Restraining FactorsMedical professionals and researchers reluctance to depend on real-world studiesNon-randomized observational studies have historically not been seen as appropriate for evaluating novel medical interventions or treatments due to methodological and research design concerns, such as the possibility of confounding and bias. 11.8.4 DYNAMIC COMPANIES R&D is particularly important in the pharmaceutical industry. Register in seconds and access exclusive features. 2.1.2.1 Key data from primary sources 1.2.1 INCLUSIONS AND EXCLUSIONS TABLE 130 JAPAN: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) TABLE 116 REST OF EUROPE: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) The 21st Century Cures Act, passed in 2016, places additional focus on the use of these types of data to support regulatory decision making, including approval of new indications for approved drugs. Who will be your Top Customer; what will make them switch? 12.2 OTHER PLAYERS Domain News - Provides the latest real estate and property market news in Australia. 6.5.2.3 Asia Pacific To meet the demands for both drug discovery and development, pharmaceutical and biopharmaceutical companies are opting for fully integrated or functional outsourcing services, from the early development stage to the late-stage development phase. Furthermore, post-pandemic, therapeutic developments for COVID-19 infection saw a significant boost. Show publisher information 7.3.1.5.1 Increasing number of disease registries is driving the demand for registry-based data sets in evidence generation TABLE 23 PHARMACY DATA SETS OFFERED BY KEY MARKET PLAYERS 10.3.4 ITALY FIGURE 30 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR MEDICAL SIMULATION PATENTS (JANUARY 2011 TO JUNE 2021) The market size for data analytics and business intelligence software applications is projected to grow over the next few years. Key companies profiled in the report include IBM Corporation, Oracle Corporation, Medpace Holdings, Inc., IQVIA Holdings, Inc., ICON plc, PerkinElmer, Inc., Parexel International Corporation (Phoenix Parentco, Inc.), PPD, Inc. (Thermo Fisher Scientific, Inc.), UnitedHealth Group, Inc. (Optum, Inc.), and Syneos Health, Inc.Strategies Deployed in Real World Evidence Solutions MarketDec-2022: IBM signed an agreement to acquire Octo, a digital transformation service provider exclusively serving the U.S. federal government. Find out more about how we use your information in our privacy policy and cookie policy. 6.7.3.2 Japan 10.4.2 CHINA FIGURE 59 CEGEDIM HEALTH DATA: COMPANY SNAPSHOT (2021) TABLE 180 ELEVANCE HEALTH: BUSINESS OVERVIEW The third table is a tabulation of the CIA World Factbook GDP (PPP) data update of 2019. Which geographical segment holds the major share of the global RWE Solutions Market? 2.5 ASSUMPTIONS FOR THE STUDY The health care community is using these data to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice. Businesses require robust evidence lifecycle management skills to demonstrate value. These variations can affect reimbursement, patient access, and potentially healthcare outcomes across health plans during the pharmaceutical technology assessment (PTA) process. Profit from the additional features of your individual account. The 21st Century Cures Act helped accelerate medical product development and brought innovations, and expanded the role of real-world evidence in the U.S. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. After the completion of each approach, the weighted average of these approaches was taken based on the level of assumptions used in each approach. 13.3 CUSTOMIZATION OPTIONS TABLE 93 FRANCE: MACROECONOMIC INDICATORS For our commercial pharma clients we integrate their commercial datasets such as ex-factory, in market sales and activity data. TABLE 148 REST OF ASIA PACIFIC: RWE SOLUTIONS MARKET, BY COMPONENT, 20202027 (USD MILLION) 6.1.5 INCORPORATION OF ARTIFICIAL INTELLIGENCE IN RWD MANAGEMENT 2.6 RISK ASSESSMENT FIGURE 20 NORTH AMERICA WILL CONTINUE TO DOMINATE THE REAL WORLD EVIDENCE SOLUTIONS MARKET DURING THE FORECAST PERIOD TABLE 159 LATIN AMERICA: REAL WORLD EVIDENCE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION) TABLE 91 UK: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 20202027 (USD MILLION) FIGURE 18 JAPAN ACCOUNTED FOR THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2021 TABLE 145 INDIA: RWE SOLUTIONS MARKET, BY APPLICATION, 20202027 (USD MILLION) Government. RWD improves likelihood of launch across all therapeutic areas - Drugs developed using real-world data had a higher likelihood of launch (89%) than the comparison group (68%), in all drugs and our three therapeutic areas. This growth in R&D expenditure, fueled by the need for numerous preclinical and clinical services during the drug development process, is expected to drive the growth of the real world evidence solutions market. 2023 MarketsandMarkets Research Private Ltd. All rights reserved, Published Date: Nov2022 | Report Code: HIT 6444, Communication and Connectivity Technology, Coatings Adhesives Sealants and Elastomers, Automotive Electronics and Electrical Equipment, Construction Technology and Sustainability, Get market data points, ranging from trend analyses to market data, Artificial Intelligence in Healthcare Market, Contract Research Organization (CRO) Services Market, Analytical and Scientific Instrumentation, Rise in the geriatric population and the subsequent increase in the prevalence of chronic diseases, Potential of RWE in reducing drug development costs and expediting the drug development process, Increased R&D spending for the development of new pharmaceutical products and medical devices, Support from regulatory bodies for the use of RWE solutions, Market Access Reimbursement/Coverage Decision Making, Pharmaceutical & Medical Device Companies. In turn, this has increased the possibility of using an end-to-end strategy to leverage a life sciences organizations data, proof, and knowledge resources. In addition, with the development of sophisticated, new analytical capabilities, we are better able to analyze these data and apply the results of our analyses to medical product development and approval. The healthcare ecosystem is changing, and there is increased scrutiny on healthcare costs as stakeholders in the healthcare industry seek new alternatives to deal with the unsustainable cost burden and relatively poor return on investment. For example, the role of RWE in drug development is expanding as RWE studies are significantly less costly and time-consuming than RCTs, providing easier access to long-term effectiveness data and helping overcome some of the feasibility barriers of running RCTs. 24*7 real-time access to a vast global inventory of hotel rooms, cars, airlines, buses, tours and other travel-related items. TABLE 156 LATIN AMERICA: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) Increased government initiatives to implement RWE studies and numerous contract research organizations (CROs) and contract research manufacturing organizations in nations like China and India are responsible for this regions rise. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.__________________________, https://www.reportlinker.com/p06422625/?utm_source=GNW. Access to this and all other statistics on 80,000 topics from, Show sources information Furthermore, it would enable the company to bring new therapies to market by leveraging these studies.Sep-2018: PAREXEL came into partnership with Datavant, a healthcare technology company focused on enabling the secure de-identification and linking of healthcare datasets. TABLE 67 CANADA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) 4.3 RWE SOLUTIONS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES Download Report. 7500+ companies worldwide approach us every year for their revenue growth initiatives. Real-world data refer to observational data as opposed to data gathered in an experimental setting such as a randomized controlled trial (RCT). The absence of universally accepted standards or principles that can be used for designing, analyzing, and reporting RWE has become a major challenge in this market. FIGURE 49 ICON PLC. The Real-world Evidence (RWE) Solutions Market is expected to reach $4.9 billion by 2029, at a CAGR of 11.8% from 2022 to 2029. RWE can be produced through various study designs or analyses, including but not limited to randomized trials, large simple trials, pragmatic trials, and observational studies (prospective or retrospective). 10.3.4.1 The demand for RWE in Italy is high due to the widespread use of pay-for-outcomes Location: New York, New York Aetion operates as a real-world evidence and analysis platform to assist the healthcare industry. The figures prior to 2020 are based on IDC's forecast from late 2018. EMERGING MARKETS TABLE 49 RWE SOLUTIONS MARKET FOR OTHER END USERS, BY COUNTRY, 20202027 (USD MILLION), 10 RWE SOLUTIONS MARKET, BY REGION (Page No. - 23) Because of these benefits, the use of real-world evidence solutions is increasing in drug and medical device R&D activities. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. The segments growth is linked to the widespread use of real-world evidence services by healthcare organizations and businesses involved in biotechnology and pharmaceuticals. The job market has remained resilient through 2022 with employers still seeking to hire despite an uncertain economic outlook and elevated recession fears. Even a study that is robust, well-planned, and non-randomized would be seen as lower-quality evidence in comparison to an RCT that is poorly conceived. Real-world evidence solutions can provide valuable insights to understand better, monitor, and prepare for the challenges caused by the COVID-19 pandemic. DownloadFree Sample Report Now @https://www.meticulousresearch.com/download-sample-report/cp_id=4954. FIGURE 29 GLOBAL PATENT PUBLICATION TRENDS IN THE RWE SOLUTIONS MARKET, 20162021 FIGURE 24 UTILIZATION OF WEARABLES IN CLINICAL TRIALS, BY THERAPEUTIC AREA, 2019 According to the Center for Drug Evaluation and Research (CDER), on average, 37 novel drugs per year were approved (including novel drugs, biosimilar, new formulations, and new dosage forms) between 2010 and 2019. 2.1.2 PRIMARY DATA TABLE 187 CLINIGEN: BUSINESS OVERVIEW TABLE 79 GERMANY: MACROECONOMIC INDICATORS TABLE 165 MIDDLES EAST & AFRICA: RWE SOLUTIONS MARKET, BY END USER, 20202027 (USD MILLION), 11 COMPETITIVE LANDSCAPE (Page No. The growth of this market is primarily driven by the increasing growth in clinical trials and the shift from volume-based to value-based care. 12.1.14 TRINITY LIFE SCIENCES TABLE 111 SPAIN: RWE MARKET, BY APPLICATION, 20202027 (USD MILLION) the controller uses real-time particle size and moisture content data as well as Fluid Bed Granulation process data to make realtime process control decisions . TABLE 129 JAPAN: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) TABLE 75 EUROPE: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) TABLE 106 ITALY: RWE MARKET, BY END USER, 20202027 (USD MILLION) 2.7.1 METHODOLOGY-RELATED LIMITATIONS, 3 EXECUTIVE SUMMARY (Page No. 10.3.2.1 The growing adoption of HTA in the UK supports market growth This insight, in clinical settings, can be gained by combining data from randomized controlled trials with evidence from real-world settings.Regional OutlookBased on Region, the Real World Evidence Solutions Market is segmented into North America, Europe, Asia Pacific, and LAMEA. Together both companies aimed at providing technology-enabled, insights-powered solutions to biopharma customers by integrating RxDataSciences AI and data-science capabilities with its therapeutic expertise.Sep-2021: Syneos Health took over StudyKIK, technology-enabled clinical trial recruitment, and retention company. 8.4.1 EMR AND PRODUCT/PATIENT REGISTRIES HAVE BECOME KEY DATA SOURCES FOR GENERATING EVIDENCE IN POST-MARKET SURVEILLANCE Among all industry sectors, the pharmaceutical industry spends the largest percentage of its revenue on research and development. 5.2.2.1 Reluctance of medical practitioners and researchers to rely on real-world studies The Big Data industry is driven by a sharp increase in data volume. FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 5.1 INTRODUCTION In addition, both companies would be able to accelerate product development in order to ensure efficiencies in patient recruitment, engagement, access, and diversity.Sep-2021: IQVIA joined hands with HealthCore, a U.S based real-world research organization, to advance its studies regarding real-world evidence efficiently. A five-year forecast of the market and noted trends. TOP 10 COMPANIES IN REAL-WORLD DATA (RWD) MARKET 0 By Meticulous Research on December 12, 2022 Healthcare, Pharmaceutical According to this latest publication from Meticulous Research, the real-world data (RWD) market is expected to register a CAGR of 7.4% from 2022 to 2029 to reach $1.66 billion by 2029. To know about the assumptions considered for the study, Request for Free Sample Report. The market is projected to grow from USD 271.83 billion in 2022 to USD 655.53 billion by 2029, exhibiting a CAGR of 13.4% during the forecast period. Feb 03, 2023 (The Expresswire) -- Platinum Catalyst Market Size is projected to Reach Multimillion USD by 2029, In comparison to 2022, at unexpected CAGR during the forecast Period 2023-2029 . (IDC, 2020) $1.9 billion will be spent in the distribution and services segment. For example, although payers have begun employing RWE, they opt to use internal observational data from randomized clinical trials (RCTs) to influence drug coverage choices. TABLE 14 RWE SERVICES MARKET, BY COUNTRY, 20202027 (USD MILLION) Real World Data (RWD), patient data that originates from real world settings delivers powerful insights to healthcare stakeholders Podcast Leveraging insights made possible by AI technology, Medical Affairs professionals are fostering better connections with healthcare professionals. This highlights the requirement for practical, workable solutions. 7.3.1.1.1 Increasing utilization of EHR data for trial recruitment to fuel growth TABLE 184 TRINITY LIFE SCIENCES: BUSINESS OVERVIEW 11.6.2 PRODUCT FOOTPRINT OF COMPANIES TABLE 136 CHINA: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) Sign up today for your free Reader Account. 11.6.1 END-USER FOOTPRINT OF COMPANIES 8.2.2 CARDIOVASCULAR DISEASE The Global Real Estate market is anticipated to rise at a considerable rate during the forecast period. TABLE 157 LATIN AMERICA: RWE SOLUTIONS MARKET, BY APPLICATION, 20202027 (USD MILLION) The global big data market in terms of revenue was estimated to be worth $162.6 billion in 2021 and is poised to reach $273.4 billion by 2026, growing at a CAGR of 11.0% from 2021 to 2026. 10.6 MIDDLE EAST & AFRICA TABLE 27 USE OF REGISTRIES FOR EVIDENCE GENERATION When typing in this field, a list of search results will appear and be automatically updated as you type. The surge is linked to the growing significance of RWE studies in determining how well drugs operate in actual situations and mitigating drug recalls. ", IDC & Statista, Volume of data/information created, captured, copied, and consumed worldwide from 2010 to 2020, with forecasts from 2021 to 2025 (in zettabytes) Statista, https://www.statista.com/statistics/871513/worldwide-data-created/ (last visited March 02, 2023), Volume of data/information created, captured, copied, and consumed worldwide from 2010 to 2020, with forecasts from 2021 to 2025 (in zettabytes) [Graph], IDC, & Statista, June 7, 2021. The growth of this market is primarily driven by the increasing growth in clinical trials and the shift from volume-based to value-based care. In addition, this further reduces the inclination of major stakeholders to adopt real world evidence solutions. TABLE 50 RWE SOLUTIONS MARKET, BY REGION, 20202027 (USD MILLION) 9.4 HEALTHCARE PROVIDERS 12.2.5 FLATIRON HEALTH, 13 APPENDIX (Page No. 12.2.1 HEALTHVERITY INC. FIGURE 11 DATA SETS MARKET, BY TYPE, 2022 VS. 2027 (USD MILLION) 6.7.3 ASIA PACIFIC Pharmaceutical and biopharmaceutical businesses are choosing fully functional or integrated outsourcing services from the early development phase to the late-stage development phase to meet the requirements for drug development and discovery due to their increasing R&D spending. FIGURE 1 RESEARCH DESIGN 12.1.8 LABCORP HOLDINGS 6.5 PRICING ANALYSIS 11.3 REVENUE SHARE ANALYSIS OF KEY PLAYERS In September 2021, U.S. FDA released a guidance document for accessing EHR and medical claims data using real-world data to support regulatory decision-making for drug and biological products would promote the adoption of RWE even further. The listing agent for these homes has added a Coming Soon note to alert buyers in advance. 6.4.2 BARGAINING POWER OF SUPPLIERS Thus, it is discovered that the usage of real-world evidence (RWE) findings is growing. Following a detailed secondary and primary research and an in-depth . 11.7.1 STARS Moreover, the processes and evidence used in making pharmaceutical coverage decisions vary substantially among the payers. TABLE 112 SPAIN: RWE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET, BY TYPE, 20202027 (USD MILLION) Access for both B2C and B2B travel booking engines. 5.2.1.3 Potential of RWE in reducing drug development costs and expediting the drug development process The data center market continued its rapid growth, with an estimated 7.4 GW online included in our 2023 rankings, as compared to 4.9 GW last year. FIGURE 52 LABCORP HOLDINGS: COMPANY SNAPSHOT (2021) TABLE 4 INDICATIVE LIST OF NATIONAL DATABASES IN DEVELOPED COUNTRIES . 11.2 STRATEGIES ADOPTED BY KEY PLAYERS /RIGHT TO WIN TABLE 183 TRINETX LLC: BUSINESS OVERVIEW Global top 2000 strategist rely on us for their growth strategies. Patient-generated data including in home-use settings, Data gathered from other sources that can inform on health status, such as mobile devices. As real world data frequently needs to combine data from multiple technology architectures including data from healthcare sources, patient reported outcomes, electronic data capture (EDC) or a mobile health technology, a highly specialized infrastructure is needed. Education. TABLE 181 SAS INSTITUTE: BUSINESS OVERVIEW 5.2.2 RESTRAINTS 12.1.17 CLINIGEN 7.3.1.3 Pharmacy data set to incorporate the statistic into your presentation at any time. - 98) Master All the Big Data Skill You Need Today Enroll Now. FIGURE 37 FDA PHASE TRANSITION SUCCESS RATES, 20112020 Many medical professionals and pharmaceutical companies have used their resources to stop the COVID-19 pandemics spread and create efficient drugs and vaccinations. TABLE 13 RWE SERVICES OFFERED BY KEY MARKET PLAYERS TABLE 16 DATA SETS MARKET, BY COUNTRY, 20202027 (USD MILLION) TABLE 162 MIDDLES EAST & AFRICA: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) TABLE 171 IQVIA HOLDINGS INC.: BUSINESS OVERVIEW 12.1.6 PAREXEL INTERNATIONAL CORPORATION 6.7 REGULATORY BODIES, GOVERNMENTS, AND OTHER ORGANIZATIONS The healthcare landscape is continuously developing and shifting towards value-based care from volume-based care. - 198) The global market of real world evidence solutions is projected to reach USD 2.9 billion. RWE experts communicate and collaborate with the subject matter experts of the pharmaceutical and medical device companies to offer services to develop intelligent RWE strategies (consulting services) and use the analytical capabilities to provide meaningful statistical insights. R&D is very important in the pharmaceutical business in particular. TABLE 88 UK: RWE SOLUTIONS DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION) FIGURE 6 MARKET SIZE ESTIMATION: SEGMENTAL EXTRAPOLATION FIGURE 54 ELEVANCE HEALTH: COMPANY SNAPSHOT (2021) In August 2022, Trinity Life Sciences (US), announced a partnership with Bain & Company (US). In 2021, the pharmaceutical, biotechnology, and medical device companies segment accounted for the largest share of the overall real-world evidence solutions market. 6.8 PATENT ANALYSIS The oncology segment dominates owing to the rising prevalence of cancer and the increasing number of clinical trials and studies focused on cancer treatment and prevention. 12.1.5 SYNEOS HEALTH, INC. The .gov means its official.Federal government websites often end in .gov or .mil. TABLE 167 REAL WORLD EVIDENCE SOLUTIONS MARKET: DETAILED LIST OF SMALL & MEDIUM PLAYERS Ltd, Cision Distribution 888-776-0942 TABLE 166 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN THE REAL WORLD EVIDENCE SOLUTIONS MARKET 11.7.4 PARTICIPANTS A paid subscription is required for full access. Some of the prominent players operating in the global RWES market are IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.) , CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), IBM Corporation (U.S.), OracleCorporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.). Factors such as the rising number of clinical trials, increasing government initiatives for the adoption of RWE studies, increasing incidences of chronic diseases, increasing demand for better healthcare services, and the rising geriatric population are supporting the growth of the RWE solutions market in the Asia Pacific region. 2.1.1 SECONDARY DATA $12 billion - the worldwide market size of AR/VR in 2020. TABLE 178 LABCORP HOLDINGS: BUSINESS OVERVIEW 10.4.1.1 Stringent regulatory scenario in Japan to restrain market growth New solution launches & enhancements enabled companies to broaden their product portfolios, advance the capabilities of existing products and services, and cater to the changing demands of users to ensure a competitive edge in the market. TABLE 82 GERMANY: DISPARATE DATA SETS MARKET, BY TYPE, 20202027 (USD MILLION)

Chesapeake Obituaries, El Corral Tucson, Articles R